Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  3,010 results for ""Dose-Response Relationship, Drug""

Your Filters

Subject : pyridines
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.

  • Authors : Feagan BG; Alimentiv, London, ON, Canada; Division of Gastroenterology, London Health Sciences Centre, Western University, London, ON, Canada. Electronic address: .

Subjects: Dose-Response Relationship, Drug* ; Remission Induction*; Colitis, Ulcerative/Colitis, Ulcerative/Colitis, Ulcerative/*drug therapy

  • Source: Lancet (London, England) [Lancet] 2021 Jun 19; Vol. 397 (10292), pp. 2372-2384. Date of Electronic Publication: 2021 Jun 03.Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X

Record details

Read More Add to Saved list
×
Academic Journal

Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study.

  • Authors : Watanabe A; Research Division for Development of Anti-Infective Agents, Faculty of Medical Science and Welfare, Tohoku Bunka Gakuen University, Sendai, Japan. Electronic address: .; Ishida T

Subjects: Dose-Response Relationship, Drug*; Antiviral Agents/Antiviral Agents/Antiviral Agents/*therapeutic use ; Influenza, Human/Influenza, Human/Influenza, Human/*drug therapy

  • Source: Antiviral research [Antiviral Res] 2019 Mar; Vol. 163, pp. 75-81. Date of Electronic Publication: 2019 Jan 23.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8109699 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.

  • Authors : Dickson MA; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York8Weill Cornell Medical College, New York, New York.; Schwartz GK

Subjects: Dose-Response Relationship, Drug*; Liposarcoma/Liposarcoma/Liposarcoma/*drug therapy ; Piperazines/Piperazines/Piperazines/*administration & dosage

  • Source: JAMA oncology [JAMA Oncol] 2016 Jul 01; Vol. 2 (7), pp. 937-40.Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.

  • Authors : Boudou-Rouquette P; Center for Research on Angiogenesis Inhibitors, Department of Medical Oncology, Cochin Teaching Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, 27 Rue du Faubourg Saint Jacques, Paris, France. ; Ropert S

Subjects: Dose-Response Relationship, Drug*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*adverse effects ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacokinetics

  • Source: The oncologist [Oncologist] 2012; Vol. 17 (9), pp. 1204-12. Date of Electronic Publication: 2012 Jul 02.Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation.

  • Authors : Chaudhary CL; College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.; Lim D

Subjects: Drug Design*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Carcinoma, Hepatocellular/Carcinoma, Hepatocellular/Carcinoma, Hepatocellular/*drug therapy

  • Source: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 844-856.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101150203 Publication Model: Print Cited Medium: Internet ISSN: 1475-6374

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC-MS/MS assay.

  • Authors : Zhang Y; Department of Pharmacy, HwaMei Hospital, University of Chinese Academy of Sciences (Ningbo No. 2 Hospital), Ningbo, China.; Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China.

Subjects: Chromatography, High Pressure Liquid/Chromatography, High Pressure Liquid/Chromatography, High Pressure Liquid/*methods ; Oxazoles/Oxazoles/Oxazoles/*pharmacokinetics ; Pyridines/Pyridines/Pyridines/*pharmacokinetics

  • Source: Pharmaceutical biology [Pharm Biol] 2022 Dec; Vol. 60 (1), pp. 621-626.Publisher: Taylor & Francis Country of Publication: England NLM ID: 9812552 Publication Model: Print Cited Medium: Internet ISSN: 1744-5116

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401).

  • Authors : Wilbaux M; Pharmacometrics, Novartis, Basel, Switzerland.; Yang S

Subjects: Piperazines*/Piperazines*/Piperazines*/pharmacology ; Pyridines*; Humans

  • Source: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2022 Dec; Vol. 112 (6), pp. 1329-1339. Date of Electronic Publication: 2022 Oct 18.Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535

Record details

Read More Add to Saved list
×
Academic Journal

Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors.

  • Authors : Lei H; Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, 110016, China.; Wang X

Subjects: Neoplasms*/Neoplasms*/Neoplasms*/drug therapy ; Phosphodiesterase Inhibitors*/Phosphodiesterase Inhibitors*/Phosphodiesterase Inhibitors*/pharmacology ; Phosphoric Diester Hydrolases*/Phosphoric Diester Hydrolases*/Phosphoric Diester Hydrolases*/metabolism

  • Source: European journal of medicinal chemistry [Eur J Med Chem] 2022 Jun 05; Vol. 236, pp. 114307. Date of Electronic Publication: 2022 Mar 25.Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 0420510 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers.

  • Authors : Wang S; Quantitative Clinical Pharmacology, Takeda Pharmaceuticals International Co., Cambridge, MA, USA.; Chen G

Subjects: Piperidines* ; Pyridines*; Adult

  • Source: British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Jun; Vol. 88 (6), pp. 2899-2908. Date of Electronic Publication: 2022 Jan 31.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Synthesis and biological evaluation of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives as novel, potent of ALK5 receptor inhibitors.

  • Authors : Wang Z; School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 210009, China; R &D Center, Nanjing Sanhome Pharmaceutical Co. Ltd., Nanjing, Jiangsu 211135, China.

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Protein Kinase Inhibitors/Protein Kinase Inhibitors/Protein Kinase Inhibitors/*pharmacology ; Pyrazoles/Pyrazoles/Pyrazoles/*pharmacology

  • Source: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2022 Apr 01; Vol. 61, pp. 128552. Date of Electronic Publication: 2022 Jan 18.Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  3,010 results for ""Dose-Response Relationship, Drug""